AI English summary of an SEC filing — figures as filed
Bristol Myers Squibb BMYBMS said its Q3 2026 revenues rose 7%, and year-to-date revenues rose 5%. The company said higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis were partially offset by generic erosion across the rest of the Legacy Portfolio.
Key points
AI summaryBMS said its Q3 2026 revenues rose 7%, and year-to-date revenues rose 5%. The company said higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis were partially offset by generic erosion across the rest of the Legacy Portfolio.
The company said its GAAP EPS fell $0.03 in Q3 2026 and its non-GAAP EPS, adjusted for specified items, fell $0.28. It cited higher one-time Acquired IPRD charges and the expiry of royalty income on diabetes products at the end of 2025 as the main factors.
Bristol Myers Squibb said its net debt position declined $4.1 billion over the 9 months ended September 30, 2026, with operating cash flow of $8.7 billion partly offset by dividend payments of $3.9 billion. It also said $1.7 billion of maturing debt was repaid over the same period.
The company said Eliquis revenues rose 25% in Q3, while Revlimid revenues fell 47%. It cited higher average net selling prices in the U.S. and higher demand as drivers of the Eliquis increase, and lower demand in the U.S. due to generic erosion as the driver of the Revlimid decline.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
BMS revenue up 7% in Q3 2026
BMS said its Q3 2026 revenues rose 7%, and year-to-date revenues rose 5%. The company said higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis were partially offset by generic erosion across the rest of the Legacy Portfolio.
Source · Based on the MD&A text of the filing
BMS GAAP EPS down $0.03 in Q3
The company said its GAAP EPS fell $0.03 in Q3 2026 and its non-GAAP EPS, adjusted for specified items, fell $0.28. It cited higher one-time Acquired IPRD charges and the expiry of royalty income on diabetes products at the end of 2025 as the main factors.
Source · Based on the MD&A text of the filing
Operating cash flow $8.7 billion over 9 months
Bristol Myers Squibb said its net debt position declined $4.1 billion over the 9 months ended September 30, 2026, with operating cash flow of $8.7 billion partly offset by dividend payments of $3.9 billion. It also said $1.7 billion of maturing debt was repaid over the same period.
Source · Based on the MD&A text of the filing
Eliquis, Revlimid revenue changes in Q3
The company said Eliquis revenues rose 25% in Q3, while Revlimid revenues fell 47%. It cited higher average net selling prices in the U.S. and higher demand as drivers of the Eliquis increase, and lower demand in the U.S. due to generic erosion as the driver of the Revlimid decline.
Source · Based on the MD&A text of the filing
Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…